Clinical Trial Update: Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating switching from imatinib to nilotinib to improve chronic low-grade adverse events in patients with Philadelphia-positive chronic myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Philadelphia Chromosome-positive

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Positive (Ph+) Chronic Myeloid Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2019-12-10